ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 594

Renal Biopsy Findings In Lupus Patient With Insignificant Proteinuria : Relation To Disease Activity and Clinical Manifestations

Abdel Azeim M. Al-Hefny1, Samah El-bakry2, Sameh A. Mobasher3, Ola H. Nada4 and Nouran Abaza5, 1Department of Internal Medicine and Rheumatology, Professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, Cairo, Egypt, 2Department of Internal Medicine and Rheumatology, Assistant professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, 3Department of Internal Medicine and Rheumatology, Lecturer of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, 4Department of Pathology, Faculty of Medicine, Ain Shams University, Lecturer of Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, 5Physical medicine, Rheumatology and Rehabilitation, Lecturer of Physical medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: biopsies, Lupus nephritis, proteinuria, renal disease and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Lupus nephritis (LN) remains one of the most serious manifestations of systemic lupus erythematosus (SLE) and is associated with significant morbidity and mortality. Early and accurate detection of kidney involvement in SLE improves outcomes. Although renal biopsy is required for proper diagnosis of the histopathological subtype of LN and direction of proper treatment, the decision to recommend renal biopsy can be complex. We aimed to investigate whether SLE patients with insignificant proteinuria have significant renal involvement and need to be biopsied. We also studied the relation between severity of nephritis and the overall disease activity and other lupus manifestations.

Methods:

Forty SLE patients with proteinuria <500 mg/24 hrs were recruited from Ain Shams University Hospitals. Disease activity was assessed according to SLE disease activity index (SLEDAI). Renal biopsy was done to all patients and assessed by light, immunofluorescent and electron microscopy for identification of different pathological classes according to WHO classification. Patients were classified into two groups: Group A: with mild renal affection [class I or II according to WHO-histopathological classification of renal biopsy] and Group B: with moderate to severe renal affection [class III, or more according to WHO classification].

Results:

All patients (100%) had lupus nephritis by histo-pathological examination according to the WHO classification. About 32.5% of SLE patients with insignificant proteinuria had mild lupus nephritis and 67.5% had moderate to severe nephritis. In Group A: 2 patients (5 %) had class I LN and 11 patients (27.5 %) had class II LN, while in Group B: 13 patients (32.5%) had class III LN, 10 patients (25 %) with class IV LN and 4 patients (10%) with class V LN. Comparing clinical characteristics of both groups; patients with severe LN (Group B) had higher SLEDAI scores (P= 0.049), higher ESR levels, higher Anti-dsDNA titer (P= 0.020) and lower C3 and C4 levels (P= 0.028 and <0.001 respectively). As well, they were more anemic, leucopenic, lymphopenic and thrombocytopenic than patients with mild LN (group A) (P= 0.020, P= 0.005, P= <0.001and P= 0.050 respectively).

Urinary abnormalities; especially proteinuria and hematuria were significantly higher in patients with severe LN than those with milder LN (P= 0.009 and 0.047 respectively). Furthermore, patients with severe LN had significant polyarthralgia and history of recurrent thrombosis than those with mild LN (P =0.011 and 0.035 respectively).

Conclusion:

We found significant renal involvement (Class III, IV, or V LN) in SLE patients with insignificant proteinuria. Our data suggest that for better outcome; renal biopsy should be justified in SLE patients with low proteinuria and without clinical signs of renal affection, especially if they have any of the following: polyarthlralgia, recurrent thrombosis, high Anti-dsDNA titer, consumed C3 &/or C4, rising ESR, high SLEDAI scores, anemia, leukopenia, lymphopenia, thrombocytopenia, and finally active urinary sediment; especially hematuria.


Disclosure:

A. A. M. Al-Hefny,
None;

S. El-bakry,
None;

S. A. Mobasher,
None;

O. H. Nada,
None;

N. Abaza,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/renal-biopsy-findings-in-lupus-patient-with-insignificant-proteinuria-relation-to-disease-activity-and-clinical-manifestations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology